Enzymatica AB (publ) (ENZY.ST)
SEK 3.4
(7.94%)
SEK 3.4
(7.94%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 11.49 Million SEK | -0.1% |
| 2022 | 11.51 Million SEK | -7.46% |
| 2021 | 12.43 Million SEK | 18.92% |
| 2020 | 10.46 Million SEK | 49.47% |
| 2019 | 6.99 Million SEK | 26.04% |
| 2018 | 5.55 Million SEK | 106.16% |
| 2017 | 2.69 Million SEK | -61.46% |
| 2016 | 6.98 Million SEK | -38.76% |
| 2015 | 11.41 Million SEK | -4.01% |
| 2014 | 11.88 Million SEK | 109.35% |
| 2013 | 5.67 Million SEK | 209.77% |
| 2012 | 1.83 Million SEK | 22.2% |
| 2011 | 1.5 Million SEK | 0.0% |
| 2009 | 186.41 Thousand SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 13.79 Million SEK | 4.25% |
| 2024 Q1 | 13.23 Million SEK | 15.11% |
| 2023 Q2 | 13.38 Million SEK | 19.31% |
| 2023 Q1 | 11.21 Million SEK | -2.55% |
| 2023 FY | 11.49 Million SEK | -0.1% |
| 2023 Q4 | 11.49 Million SEK | 1.59% |
| 2023 Q3 | 11.31 Million SEK | -15.42% |
| 2022 Q4 | 11.51 Million SEK | -11.53% |
| 2022 Q1 | 13.37 Million SEK | 7.52% |
| 2022 FY | 11.51 Million SEK | -7.46% |
| 2022 Q3 | 13.01 Million SEK | -1.56% |
| 2022 Q2 | 13.21 Million SEK | -1.18% |
| 2021 FY | 12.43 Million SEK | 18.92% |
| 2021 Q4 | 12.43 Million SEK | -7.56% |
| 2021 Q2 | 13.96 Million SEK | -7.45% |
| 2021 Q1 | 15.08 Million SEK | 44.2% |
| 2021 Q3 | 13.45 Million SEK | -3.61% |
| 2020 Q2 | 9.92 Million SEK | 29.79% |
| 2020 Q3 | 9.63 Million SEK | -2.86% |
| 2020 Q4 | 10.46 Million SEK | 8.55% |
| 2020 FY | 10.46 Million SEK | 49.47% |
| 2020 Q1 | 7.64 Million SEK | 9.22% |
| 2019 FY | 6.99 Million SEK | 26.04% |
| 2019 Q1 | 6.98 Million SEK | 25.86% |
| 2019 Q2 | 7.07 Million SEK | 1.17% |
| 2019 Q3 | 5.72 Million SEK | -19.01% |
| 2019 Q4 | 6.99 Million SEK | 22.21% |
| 2018 Q1 | 5.76 Million SEK | 114.18% |
| 2018 FY | 5.55 Million SEK | 106.16% |
| 2018 Q3 | 5.59 Million SEK | -19.58% |
| 2018 Q2 | 6.95 Million SEK | 20.6% |
| 2018 Q4 | 5.55 Million SEK | -0.75% |
| 2017 Q3 | 2.08 Million SEK | -55.66% |
| 2017 Q1 | 6.41 Million SEK | -8.22% |
| 2017 Q4 | 2.69 Million SEK | 29.28% |
| 2017 FY | 2.69 Million SEK | -61.46% |
| 2017 Q2 | 4.69 Million SEK | -26.74% |
| 2016 Q4 | 6.98 Million SEK | -19.64% |
| 2016 FY | 6.98 Million SEK | -38.76% |
| 2016 Q2 | 10.83 Million SEK | 8.54% |
| 2016 Q3 | 8.69 Million SEK | -19.77% |
| 2016 Q1 | 9.98 Million SEK | -12.5% |
| 2015 Q3 | 13.01 Million SEK | -5.42% |
| 2015 Q2 | 13.76 Million SEK | 37.77% |
| 2015 Q4 | 11.41 Million SEK | -12.33% |
| 2015 Q1 | 9.98 Million SEK | -15.98% |
| 2015 FY | 11.41 Million SEK | -4.01% |
| 2014 Q2 | 8.65 Million SEK | 7.56% |
| 2014 Q4 | 11.88 Million SEK | 29.86% |
| 2014 Q3 | 9.15 Million SEK | 5.78% |
| 2014 FY | 11.88 Million SEK | 109.35% |
| 2014 Q1 | 8.04 Million SEK | 41.7% |
| 2013 Q4 | 5.67 Million SEK | 144.74% |
| 2013 Q3 | 2.32 Million SEK | -21.3% |
| 2013 FY | 5.67 Million SEK | 209.77% |
| 2013 Q1 | 1.6 Million SEK | -12.38% |
| 2013 Q2 | 2.94 Million SEK | 83.56% |
| 2012 Q2 | 1.25 Million SEK | -1.01% |
| 2012 Q3 | 1.81 Million SEK | 44.82% |
| 2012 Q1 | 1.26 Million SEK | 0.0% |
| 2012 Q4 | 1.83 Million SEK | 0.8% |
| 2012 FY | 1.83 Million SEK | 22.2% |
| 2011 FY | 1.5 Million SEK | 0.0% |
| 2011 Q3 | 1.59 Million SEK | -7.18% |
| 2011 Q2 | 1.72 Million SEK | 0.0% |
| 2009 FY | 186.41 Thousand SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| AcuCort AB | -1.09 Million SEK | 1146.315% |
| AlzeCure Pharma AB (publ) | -2508.00 SEK | 458592.823% |
| BioGaia AB (publ) | 181.2 Million SEK | 93.654% |
| Enorama Pharma AB (publ) | 4.29 Million SEK | -167.917% |
| Gabather AB (publ) | -1772.00 SEK | 649027.765% |
| Klaria Pharma Holding AB (publ.) | - SEK | -Infinity% |
| Moberg Pharma AB (publ) | 7.11 Million SEK | -61.616% |
| Nanexa AB (publ) | 1.91 Million SEK | -501.727% |
| Newbury Pharmaceuticals AB (publ) | 4.99 Million SEK | -130.21% |
| ODI Pharma AB | - SEK | -Infinity% |
| Orexo AB (publ) | 42.4 Million SEK | 72.88% |
| Probi AB (publ) | 116.7 Million SEK | 90.147% |
| Swedencare AB (publ) | 398.1 Million SEK | 97.112% |
| Swedish Orphan Biovitrum AB (publ) | 3.87 Billion SEK | 99.703% |
| Toleranzia AB | -1.34 Million SEK | 958.134% |
| Vivesto AB | - SEK | -Infinity% |